Innovating.works Conecta tu I+D

Mostrando 1 al 20 de 88 resultados

MITI 2: Gut Microbiota-Induced Tregs for Inflammatory-Bowel-Disease (IBD) Immunotherapy (MITI2) INSERM TRANSFERT SA participó en un HORIZON EUROPE: HORIZON-HLTH-2022-DISEASE-06-two-stage Our project focuses on the regulatory properties of a subset of microbiota-specific TR1-like regulatory T (Treg) cells, for which we have al...
2023-04-28 - 2027-04-30 | Financiado

ARTiDe: Autoantigen-specific adoptive regulatory T cell therapy against type 1 diabetes (ARTiDe) INSERM TRANSFERT SA participó en un HORIZON EUROPE: HORIZON-HLTH-2022-DISEASE-06-two-stage Type 1 diabetes (T1D) is an incurable disease, often starting in childhood, with a risk of devastating complications, premature mortality, a...
2023-04-27 - 2028-06-30 | Financiado

MPX-RESPONSE: A clinical research network to improve the management of Monkeypox virus disease INSERM TRANSFERT SA participó en un HORIZON EUROPE: The 2022 Monkeypox outbreak is unprecedented in scale and cases are still active in South America and starting to appear in South-East Asia....
2023-04-14 - 2026-08-04 | Financiado

4.UNCAN.eu: A Coordination and Support Action to prepare UNCAN.eu platform INSERM TRANSFERT SA participó en un HORIZON EUROPE: HORIZON-MISS-2021-UNCAN-01 The 15-month coordination and support action 4.UNCAN.eu will generate a strategic agenda to launch UNCAN.eu, a European initiative to UNders...
2022-05-17 - 2023-11-30 | Financiado

ISIDORe: Integrated Services for Infectious Disease Outbreak Research INSERM TRANSFERT SA participó en un HORIZON EUROPE: HORIZON-INFRA-2021-EMERGENCY-02 The ISIDORe consortium, made of the capacities of European ESFRI infrastructures and coordinated networks, proposes to assemble the largest...
2022-02-09 - 2025-07-31 | Financiado

CBIG-SCREEN: Working collaboratively with vulnerable women to identify the best implementation gains by screening... INSERM TRANSFERT SA participó en un H2020: H2020-SC1-BHC-2018-2020 CBIG-SCREEN aims to tackle inequality in cervical cancer screening (CCS) continuum. Though CCS programmes drastically reduce cervical cancer...
2021-02-02 - 2026-02-28 | Financiado

RITA-MI 2: Rituximab in patients with acute myocardial infarction a phase 2 placebo controlled randomised clin... INSERM TRANSFERT SA participó en un H2020: H2020-SC1-BHC-2018-2020 RITA-MI 2 will assess the impact of a novel therapeutic strategy targeting patients’ immune response on the recovery of heart function after...
2021-01-18 - 2026-05-31 | Financiado

EU-RESPONSE: European Research and Preparedness Network for Pandemics and Emerging Infectious Diseases INSERM TRANSFERT SA participó en un H2020: The overall objective of this 5-year project is to build a multinational, adaptive European COVID-19 and emerging infectious diseases trial...
2020-09-03 - 2025-06-30 | Financiado

MAD-CoV 2: Modern approaches for developing antivirals against SARS CoV 2 INSERM TRANSFERT SA participó en un H2020: H2020-JTI-IMI2-2020-21-single-stage The SARS-CoV-2 pandemic has become an unprecedented burden to public health, our civil societies and the global economy. To provide frontlin...
2020-08-11 - 2025-07-31 | Financiado

CARE: Corona Accelerated R D in Europe INSERM TRANSFERT SA participó en un H2020: H2020-JTI-IMI2-2020-21-single-stage The Severe Acute Respiratory Syndrome coronavirus 2 (SARS-CoV-2) pandemic has emerged as the largest global health threat to humanity in thi...
2020-08-07 - 2025-03-31 | Financiado

PREMSTEM: Brain injury in the premature born infant stem cell regeneration research network INSERM TRANSFERT SA participó en un H2020: H2020-SC1-BHC-2018-2020 This project will provide new knowledge regarding the best regimen, timing, dose, and route of administration of human mesenchymal stem cell...
2019-12-06 - 2025-12-31 | Financiado

FAIR: FLAGELLIN AEROSOL THERAPY AS AN IMMUNOMODULATORY ADJUNCT TO THE ANTIBIOTIC TREATMENT OF DRUG RESISTA... INSERM TRANSFERT SA participó en un H2020: H2020-SC1-BHC-2018-2020 Bacterial pneumonia is a leading cause of morbidity and mortality worldwide. Antibiotics constitute the standard of care but are faced with...
2019-12-06 - 2025-06-30 | Financiado

REMEDIA: Impact of exposome on the course of lung diseases INSERM TRANSFERT SA participó en un H2020: H2020-SC1-BHC-2018-2020 Chronic obstructive pulmonary disease (COPD) and cystic fibrosis (CF) are two very debilitating non-communicable diseases that are of partic...
2019-12-06 - 2024-12-31 | Financiado

miniNO: Associative mechanisms linking a defective minipuberty to the appearance of mental and nonmental dis... INSERM TRANSFERT SA participó en un H2020: H2020-SC1-BHC-2018-2020 The miniNO project aims to identify the key causative mechanisms of the lifelong multimorbidity associated with preterm birth. Prematurity i...
2019-12-05 - 2025-12-31 | Financiado

IP-cure-B: Immune profiling to guide host directed interventions to cure HBV infections INSERM TRANSFERT SA participó en un H2020: H2020-SC1-BHC-2018-2020 The objective of the project is to develop novel curative concepts for chronic hepatitis B (CHB). Specific aims will be to: 1) improve the r...
2019-12-05 - 2024-12-31 | Financiado

TheraLymph: Gene Therapy to restore lymphatic flow lymphedema INSERM TRANSFERT SA participó en un H2020: H2020-SC1-BHC-2018-2020 Lymphedema is a disabling condition induced by the accumulation of fluid and fat in the arm or in the leg. It is an untreatable disease that...
2019-11-24 - 2025-06-30 | Financiado

HUGODECA: Human Gonad Developmental Cell Atlas INSERM TRANSFERT SA participó en un H2020: H2020-SC1-BHC-2018-2020 The single ground-breaking goal of the HUGODECA project is to describe the cellular composition and organization of the developing human gon...
2019-11-24 - 2022-06-30 | Financiado

AB-DiRecT: Antibiotic Distribution and Recovery in Tissue INSERM TRANSFERT SA participó en un H2020: H2020-JTI-IMI2-2018-16-single-stage Antimicrobial resistance imposes an important health and economic burden with the threat of a future without effective antibiotics requiring...
2019-06-25 - 2023-09-30 | Financiado

CARDIATEAM: CARdiomyopathy in type 2 DIAbetes mellitus INSERM TRANSFERT SA participó en un H2020: H2020-JTI-IMI2-2017-13-two-stage A rapidly evolving epidemic in Type 2 Diabetes (T2DM) is afflicting all ages, sexes and socioeconomic classes which includes serious comorbi...
2019-04-11 - 2026-02-28 | Financiado

EJP RD: European Joint Programme on Rare Diseases INSERM TRANSFERT SA participó en un H2020: H2020-SC1-BHC-2018-2020 As recognized by the Council Recommendation 2009/C 151/02, rare diseases (RD) are a prime example of a research area that can strongly profi...
2018-12-13 - 2024-08-31 | Financiado